Results 181 to 190 of about 3,571,431 (286)

Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio. [PDF]

Pharmacoeconomics, 2020
Alarid-Escudero F, Kuntz KM.
europepmc   +1 more source

Increased Hazard Ratio of a Second ACL Injury After Return to Sport for Each Positive Hypermobility Test on the Beighton Score: A Registry Study. [PDF]

Sports Med Open
Lindskog J, Zsidai B, Sundberg A, Högberg J, Hamrin Senorski R, Liaghat B, Samuelsson K, Thomeé R, Piussi R, Hamrin Senorski E.   +9 more
europepmc   +1 more source

POOLING AND REDISTRIBUTION WITH MORAL HAZARD [PDF]

We study a model in which risk-averse consumers obtain mutual insurance by participating voluntarily in pools. More precisely, consumers commit to contributing a fraction of their future uncertain endowment to a common pool.
Catarina Goulão, Luca Panaccione
core  

Early Clinical, Imaging, and Pathological Characteristics of SRPK3/TTN‐Digenic Myopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SRPK3/TTN‐digenic myopathy was recently established as a skeletal muscle myopathy caused by digenic inheritance. This study characterizes the early clinical presentation of SRPK3/TTN‐digenic myopathy in one previously reported and seven newly identified pediatric patients.
Rotem Orbach, Sandra Donkervoort, Carola Hedberg‐Oldfors, Giovanni Baranello, Dimah Saade, Precilla D'Souza, Ruchee Patel, Eva Michael, A. Reghan Foley, Diana Bharucha‐Goebel, S. Jin Haugland, Meghan McAnally, Omer Abdul Hamid, Katherine Chao, Ellen F. Macnamara, Alan H. Beggs, Anna Sarkozy, Juliane Mueller, Steven A. Moore, Richard S. Finkel, Cynthia J. Tifft, Francesco Muntoni, Anders Oldfors, Carsten G. Bönnemann   +23 more
wiley   +1 more source

Instrumental variable estimation of a hazard ratio for treatment with a waiting time without specifying its dependence on unmeasured confounders: application to a procedural registry. [PDF]

Lifetime Data Anal
MacKenzie TA, Martínez-Camblor P, Chen H, Columbo JA, O'Malley AJ.   +4 more
europepmc   +1 more source

Moral hazard and ambiguity

, 2010
We consider a principal-agent model with moral hazard where the agent’s knowledge about the performance measure is ambiguous and he is averse towards ambiguity.
Weinschenk, Philipp 1979-
core  

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

EMERGING MARKET LENDING: IS MORAL HAZARD ENDOGENOUS? [PDF]

This paper shows how growth in financially open developing countries is affected when relations with international lenders suffer from the danger of moral hazard.
Tobias Broer
core  

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Novel insights into SGLT2 inhibitor efficacy in heart failure: A meta-analysis employing win ratio, hazard ratio, and risk ratio. [PDF]

Am Heart J Plus
Nasrollahizadeh A, Javankiani S, Rahmati S, Nasrollahizadeh A, Hakim D, Modin D, Johansen ND, Biering-Sørensen T, Hosseini K.   +8 more
europepmc   +1 more source